Tim G. Larson, MD, oncologist, Minnesota Oncology, discusses ongoing trials in colorectal cancer (CRC).

The BEACON trial is looking at patients with 

 mutations, which is a small subset of patients with CRC who have a poor prognosis and do not respond to the standard treatments. This trial is offering these patients promising therapies, says Larson.

A different phase III trial is examining the effectiveness of napabucasin (BBI-608), an oral cancer stem cell inhibitor, in the second-line setting.

Videos

Dr. Larson on Ongoing Trials in Colorectal Cancer

Tim G. Larson, MD, Minnesota Oncology discusses the development of immunotherapy for patients with colorectal cancer (CRC).

Immunotherapies have seen success in patients with microsatellite instability-high (MSI-H) CRC even though this only includes a small percentage of patients, states Larson. Patients with microsatellite stable (MSS) CRC have not seen the same results but this is under current investigation since they make up 95% of the patient population.

Unique combinations or molecules might show some signs of progress for these patients, explains Larson.

Tim G. Larson, MD

Articles

Dr. Larson on Ongoing Trials in Colorectal Cancer

Dr. Larson on Immunotherapy for Colorectal Cancer